WallStSmart

Danaher Corporation (DHR)vsPrenetics Global Ltd (PRE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Danaher Corporation generates 26492% more annual revenue ($24.57B vs $92.39M). DHR leads profitability with a 14.7% profit margin vs -63.1%. DHR earns a higher WallStSmart Score of 60/100 (C).

DHR

Buy

60

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 7.3Quality: 6.3
Piotroski: 4/9Altman Z: 2.36

PRE

Avoid

35

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DHRSignificantly Overvalued (-38.6%)

Margin of Safety

-38.6%

Fair Value

$135.07

Current Price

$187.15

$52.08 premium

UndervaluedFair: $135.07Overvalued

Intrinsic value data unavailable for PRE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DHR4 strengths · Avg: 8.3/10
Market CapQuality
$134.43B9/10

Large-cap with strong market position

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.2%8/10

Strong operational efficiency at 22.2%

Free Cash FlowQuality
$1.75B8/10

Generating 1.7B in free cash flow

PRE1 strengths · Avg: 8.0/10
Price/BookValuation
2.0x8/10

Reasonable price relative to book value

Areas to Watch

DHR3 concerns · Avg: 3.7/10
P/E RatioValuation
37.7x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.6%4/10

4.6% revenue growth

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

PRE4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
2.5%4/10

2.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$361.14M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-31.8%2/10

ROE of -31.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : DHR

The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.23 suggests the stock is reasonably priced for its growth.

Bull Case : PRE

The strongest argument for PRE centers on Price/Book.

Bear Case : DHR

The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.

Bear Case : PRE

The primary concerns for PRE are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

DHR profiles as a value stock while PRE is a turnaround play — different risk/reward profiles.

DHR carries more volatility with a beta of 0.96 — expect wider price swings.

DHR is growing revenue faster at 4.6% — sustainability is the question.

DHR generates stronger free cash flow (1.7B), providing more financial flexibility.

Bottom Line

DHR scores higher overall (60/100 vs 35/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Danaher Corporation

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.

Prenetics Global Ltd

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Prenetics Global Ltd (PRE) is a leading health technology innovator specializing in genetic and diagnostic testing, leveraging advanced technologies to provide essential health insights for consumers and healthcare professionals alike. The company boasts a comprehensive portfolio of cutting-edge genetic testing solutions and integrated digital health services, driving its robust international growth through strategic partnerships and an unwavering dedication to research and development. Positioned at the forefront of personalized medicine, Prenetics is well-equipped to meet the growing consumer demand for accessible and actionable health information, making it a compelling investment opportunity in the rapidly evolving healthcare sector.

Want to dig deeper into these stocks?